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Abstract
Methadone maintenance therapy for the treatment of opioid dependence continues to carry a
social stigma. Until recently, patients on methadone were not considered for liver transplantation.
We describe the first case of a patient on methadone who received a liver transplant for end stage
liver disease and was successfully treated for recurrent hepatitis C. More than five years post
transplant and three years post viral clearance, the patient continues to do well and is stable on
low-dose methadone. This case emphasizes the need to reconsider the non-evidence based policy
adopted by transplant centers that require methadone maintenance therapy patients to stop
methadone prior to consideration for transplant evaluation.
Background
Although there are years of data proving methadone as a
highly effective treatment for opioid dependence, metha-
done maintenance therapy (MMT) continues to be a bar-
rier to standard medical care. Even today, there is a general
misconception that MMT patients make poor candidates
for liver transplantation (LT) despite the lack of evidence
that their overall outcome differs from non-MMT patients
[1,2]. In 2000, a nationwide survey showed that only 56%
of responding transplant centers (90% of the queried)
considered active MMT patients for transplant waiting
lists; however, 32% of respondents required patients to
cease methadone prior to transplantation [3].
In our transplant center at UC Davis Medical Center
(UCDMC), patients referred for liver transplant undergo
standard psycho-social, financial, medical, and surgical
evaluations. Patients who meet the criteria for substance
dependence sign an abstinence agreement which may
require toxicology screenings and documented attend-
ance to Narcotics/Alcoholics Anonymous meetings (NA
and AA, respectively). Patients on methadone are not
excluded or required to cease MMT, although they may be
expected to attend NA. The duration and consistency of
attendance to the MMT program, including routine toxi-
cology screenings and counseling, are considered by the
LT selection committee on a case by case basis. UCDMC
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HCV is highly prevalent in MMT patients[4]. Although a
recent study showed that MMT patients did have a slightly
decreased sustained virological response (SVR) to antivi-
ral therapy with interferon (IFN) and ribavirin (RBV)
(28%), it clearly showed that treatment is possible [5].
The disparity in response rates can be attributed to many
factors including smaller cohort size and selected patient
population (clinical degree of liver disease, concurrent
mental illness, and current or recent substance abuse).
Our case demonstrates that a patient on MMT can receive
LT and successfully be treated for HCV recurrence post
transplant.
Case report
In August 2000, a 37 year old Native-American male
received a cadaveric liver transplant after approximately
20 years of chronic HCV infection, genotype 1a. He was a
former intravenous drug user (IVDU) and had been
enrolled in a MMT program since 1990, taking between
80 and 100 mg methadone daily. He also had a history of
anxiety and mood disorders, and had been taking clon-
azepam, 1 mg 4 times daily since 1999. At transplant eval-
uation, the patient had solid psychosocial support (family
and counseling) and had a consistent ten year adherence
to his MMT, including negative toxicological screens. The
UCDMC transplant team determined that it would be in
the patient's best interest to continue his MMT pre and
post transplant.
The patient had a MELD score of 15 at the time of trans-
plant. He tolerated the operation well with no major com-
plications during surgery, although he did require more
intraoperative anesthesia than the average non-MMT
patient. Post-operative pain management during hospital-
ization required consultation with pain specialists and the
doses of hydromorphone and morphine were higher than
the average non -MMT transplant patients. On post-oper-
ative day six, the patient resumed a normal diet; his pain
was managed with oral narcotic analgesics; he was fully
ambulatory and was discharged from the hospital. Imme-
diately post-transplant, the patient's methadone was 100
mg daily.
In June 2001, the patient showed biopsy proven recurrent
HCV in the transplanted liver. There were no signs of
rejection. The patient was continuing MMT ~80 mg daily
and was compliant with his immunosuppressive therapy
and transplant follow up care. In January 2002, the
patient began HCV treatment using an escalating regimen
of INF combined with RBV. He reached full dose INF (3
MIU three times per week) and RBV (1200 mg daily) at
approximately 10 weeks of treatment. The intention was
to treat for 48 weeks on combination therapy. The patient
started treatment with a low viral load (410,760 IU/mL).
At approximately six months of therapy, he was HCV-RNA
quantitatively virus negative.
Overall, the patient had common side effects to the com-
bination therapy. His physical symptoms included
fatigue, nausea, headaches, and flu-like symptoms. These
side effects were treated symptomatically and either
resolved or were well-tolerated. Although the patient was
taking immunosuppressive drugs throughout his HCV
therapy, his white blood cell and absolute neutrophil
counts remained stable. By treatment week 12, he did
experience significant hemolytic anemia (Hgb 10.7 g/dL)
and was started on 40,000 units per week of erythropoie-
tin. The patient's RBV was reduced to 800 mg daily for two
weeks and then was increased to 1000 mg daily for the
remainder of treatment.
Due to a history of anxiety and mood disorders, the
patient was started on low dose antidepressants, citalo-
pram 10 mg daily, three months prior to starting treat-
ment. Additionally, the patient experienced psychiatric
side effects to IFN/RBV including mood swings, angry out-
bursts, insomnia, and forgetfulness. His citalopram, 10
mg daily, was increased twice (20 mg daily at week 12 and
40 mg daily at week 40). Quetiapine, 25 mg 1–2 tabs
daily, and bupropion, 150 mg twice daily, were also
added halfway through treatment to further control these
psychiatric side effects. These additional psychotropic
medications were managed in conjunction with the
patient's methadone clinic; during treatment the patient's
methadone was gradually increased from 84 mg daily to a
maximum of 110 mg daily. Twenty-four weeks after treat-
ment, the patient's methadone was reduced to 80 mg
daily and has incrementally decreased to his current dose
of 4 mg daily in 2006. The patient has continued to take
clonazepam, 1 mg 3 times daily, and quetiapine, 50 mg
daily, post treatment. In 2004, he was able to find a job
after many years of unemployment. In 2006, four years
after treatment, he continues to be: (a) HCV free with
annual liver biopsies showing no signs of disease or fibro-
sis, (b) stable on immunosuppression, (c) on minimal
doses of methadone (15 mg/d), and (d) compliant with
medical advice and medications.
Discussion
Stigma regarding methadone maintenance therapy con-
tinues to be a barrier to patients receiving liver transplant
and standard HCV treatment. Although methadone is a
widely-accepted, highly effective treatment for opiate
addiction, MMT patients continue to be discriminated
against. The primary reason for this bias was investigated
in a 2000 survey which showed that most transplant cent-Page 2 of 4
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clusion was that there was a significant misunderstanding
between heroin dependency and methadone mainte-
nance therapy as treatment[1]. More specifically, metha-
done is often seen as an abused drug, not as a treatment
for opiate addiction. Thus, MMT patients may still be per-
ceived as not fully "recovered"; they are treated as if they
are "addicted" to a drug (i.e., methadone) and are not
"worthy or ready" for standard medical care, such as treat-
ment of HCV and LT. Many transplant centers require
patients to discontinue MMT before they can be consid-
ered for transplant – a practice which may be considered
unethical and harmful; however, there is an emerging
opinion to support the cautious inclusion of MMT patient
in liver transplantation [6,7].
The NIH 2002 Consensus Statement on HCV manage-
ment clearly supports methadone treatment for opiate
addiction. The document states that methadone helps
reduce risky behaviors and should not be used as a reason
to exclude a patient from HCV treatment. Additionally it
affirms that methadone patients (and even active IVDUs
and alcoholics) can be treated successfully for HCV [8].
Model MMT patients have a proven track record of medi-
cal follow up appointments, repeated laboratory studies,
and adherence to taking their methadone. It has been sug-
gested that patients enrolled in MMT are the best candi-
dates for HCV therapy among IVDUs [9].
Opioid dependent patients may have pre-existing mood
and/or anxiety disorders. In addition, these patients are at
risk for IFN-associated mood disturbances. When these
patients are treated for mood and/or anxiety disorders
with antidepressants, physicians are advised to monitor
doses, side effects, and drug-drug interactions closely and
make medication changes as needed [10].
MMT patients who undergo LT require more intraopera-
tive anesthesia and postoperative analgesia than non-
MMT patients [11]. Our patient is no exception. However,
this should not be used as an argument to deny LT for
MMT patients.
Our case study demonstrates that a correctly evaluated
patient on MMT can achieve SVR even after LT. Although,
organ transplantation and decompensated cirrhosis are
on the list of contraindications for use of IFN-based ther-
apy, most transplant hepatologists are now treating both
difficult to treat groups. It would be ideal for HCV patients
to clear the virus before transplant since reinfection of the
graft after liver transplant in patients who are HCV posi-
tive at the time of transplant is universal [12]. In addition,
due to the donor shortage, many centers have adopted
expanded donor policies that include transplanting HCV
positive donors to HCV positive recipients. However,
those rare patients who are able to clear the virus with
therapy before liver transplant have a low rate of recur-
rence and should not receive HCV positive livers.
To our knowledge, this is the first report of successful
treatment of HCV post-transplant in an MMT patient. We
recommend that patients on MMT needing a liver trans-
plant should not be required to stop taking methadone.
We believe that each patient should be evaluated inde-
pendently and equally as far as their history and compli-
ance behavior. Furthermore, although HCV treatment
may be more difficult in transplant patients on immuno-
suppression and methadone, it should be considered and
tested in larger trials.
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